Prescription medicine
Frovatriptan First approved as Frova
Frovatriptan (Frova) is a prescription medicine with an FDA approval on record since 2001. FDA's NDC Directory lists it from 4 generic labelers, and pharmacies paid $2.72 per frovatriptan succ 2.5 mg tablet in the October 7, 2026 NADAC survey.
- Generic listed
- A presentation discontinued
Check it at the source: the frovatriptan FDA label on DailyMed (effective June 27, 2026, Leading Pharma, LLC); the NDA 21006 record on Drugs@FDA; every frovatriptan label on DailyMed.
Highlights of the record
FDA label of June 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageFrovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults.
Forms and strengths
- 2.5 mg
Film-coated tablet.
On the market
- Earliest approval on file
- November 8, 2001 Frova, Endo Operations; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 5 first August 28, 2014; 4 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 4 of which 4 under generic applications, 0 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $2.72 per tablet Frovatriptan succ 2.5 mg tablet
- Shortage (FDA)
- None current 2 past records
- Recalls by its makers (FDA)
- 2 since 2020 0 Class I among all firms' recalls; latest March 13, 2025
- FAERS reports
- 772 through July 30, 2026
What is frovatriptan used for?
From the label: indications and usageFrovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks. Frovatriptan succinate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of frovatriptan succinate tablets have not been established for cluster headache. […]
Conditions named in the indications of frovatriptan's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Serotonin-1b and Serotonin-1d Receptor Agonist.
Source: FDA drug label (FROVATRIPTAN SUCCINATE), Leading Pharma, LLC, effective June 27, 2026 (SPL set d303af88-e0c1-4fb2-ba8e-83b7e6d163cd), via openFDA; the full label on DailyMed
What does the patient leaflet for frovatriptan say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about frovatriptan succinate tablets?Frovatriptan succinate tablets can cause serious side effects, including: Heart attack and other heart problems. Heart problems may lead to death. Stop taking frovatriptan succinate tablets and get emergency medical help right away if you have any of the following symptoms of a heart attack: discomfort in the center of your chest that lasts for more than a few minutes, or that goes away and comes back severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw pain or discomfort in your arms, back, neck, jaw, or stomach shortness of breath with or without chest discomfort breaking out in a cold sweat nausea or vomiting feeling lightheaded Frovatriptan succinate tablets are not for people with risk factors for heart disease unless a heart exam is done and shows no problem. You have a higher risk for heart disease if you: have high blood pressure smoke have diabetes have high cholesterol levels are overweight have a family history of heart disease
From the patient leaflet: What should I avoid while taking frovatriptan succinate tablets?Frovatriptan succinate tablets can cause dizziness, weakness, or drowsiness. If you have these symptoms do not drive a car, use machinery, or do anything where you need to be alert.
From the patient leaflet: How should I store frovatriptan succinate tablets?Store frovatriptan succinate tablets between 68°F to 77°F (20°C to 25°C). Protect frovatriptan succinate tablets from moisture. Throw away (discard) after expiration date printed on the carton. Keep frovatriptan succinate tablets and all medicines out of the reach of children.
Source: FDA drug label (FROVATRIPTAN SUCCINATE), Leading Pharma, LLC, effective June 27, 2026 (SPL set d303af88-e0c1-4fb2-ba8e-83b7e6d163cd), via openFDA; the full label on DailyMed
Is there a generic for frovatriptan (Frova)?
The FDA approved the first generic frovatriptan on August 28, 2014. 5 generic applications are approved; 4 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists frovatriptan from 4 labelers under a generic (ANDA) application. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 2001 earliest approval on file
- 2014 first generic approved
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for frovatriptan (Frova)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $2.72 per Frovatriptan succ 2.5 mg tablet, down 21% from $3.45 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Frovatriptan succ 2.5 mg tablet (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Frovatriptan succ 2.5 mg tablet | Generic | $2.72 per tablet | $81.51 | -21% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is frovatriptan in shortage?
No frovatriptan presentation is listed as in shortage in the FDA Drug Shortage Database (read October 8, 2026); its 2 records are all marked to be discontinued, the latest updated February 24, 2026. ASHP keeps a separate shortage list, which can differ.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Frova, Tablet, 2.5 mg (NDC 0603-3718-34) | Endo Pharmaceuticals, Inc. | To Be Discontinued | November 12, 2025 |
| Frova, Tablet, 2.5 mg (NDC 63481-025-09) | Endo Pharmaceuticals, Inc. | To Be Discontinued | February 24, 2026 |
Every frovatriptan presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has frovatriptan been recalled?
The FDA's Enforcement Report lists 2 recalls naming frovatriptan since 2020: 0 Class I (the most serious), 1 Class II, 1 Class III; 1 still ongoing. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| March 13, 2025 | Class II | Glenmark Pharmaceuticals Inc., USA | CGMP Deviations |
| February 10, 2020 | Class III | Par Pharmaceutical Inc. | Labeling: Incorrect or Missing Lot and/or Exp Date: Product incorrectly labeled with an expiration date of August 2022 rather than the correct expiration date … |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the frovatriptan label say about other medicines?
The frovatriptan label names 2 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Dihydroergotamine | contraindications | Recent use (i.e., within 24 hours) of another 5-HT 1 agonist, an ergotamine containing or ergot-type medication such as dihydroergotamine (DHE) or methysergide [see Drug Interactions (7.1 , 7.2) ]. |
| Ergotamine | warnings and precautions | Overuse of acute migraine drugs (e.g., ergotamine, triptans, opioids, or combination of these drugs for 10 or more days per month) may lead to exacerbation of headache (medication overuse headache). |
Source: FDA drug label (FROVATRIPTAN SUCCINATE), Leading Pharma, LLC, effective June 27, 2026 (SPL set d303af88-e0c1-4fb2-ba8e-83b7e6d163cd), via openFDA; the full label on DailyMed
What do FAERS reports show for frovatriptan?
The FDA Adverse Event Reporting System holds 772 reports that list frovatriptan among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 6 are coded as a death and 134 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as frovatriptan?
12 other medicines are given the same way (oral) and in the same FDA class as frovatriptan or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 22 labelers | $0.302 per tablet 50 mg tablet | No current entry |
| Rizatriptan | Migraine | 25 labelers | $0.335 per tablet 10 mg tablet | No current entry |
| Zolmitriptan | Migraine | 18 labelers | $1.02 per tablet 2.5 mg tablet | No current entry |
| Eletriptan | Migraine | 10 labelers | $1.75 per tablet 40 mg tablet | No current entry |
| Naratriptan | Migraine | 4 labelers | $1.08 per tablet 2.5 mg tablet | No current entry |
| Almotriptan | Migraine | 3 labelers | $16.86 per tablet 12.5 mg tablet | No current entry |
| Naproxen and sumatriptan | Migraine | 3 labelers | $10.46 per unit 85-500 mg | No current entry |
| Meloxicam and rizatriptan | Migraine | none listed | $122.64 per tablet 20-10 mg tablet | No current entry |
Every medicine labeled for the same conditions as frovatriptan
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to frovatriptan
- 12 medicines for the same use
- Other triptans
- the pharmacologic class, with prices and generics
- Frovatriptan side effects
- the label's list beside FAERS reports
- Frovatriptan shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other